|1.||Pazoles, Christopher J: 3 articles (05/2012 - 04/2008)|
|2.||Tew, Kenneth D: 3 articles (01/2010 - 04/2008)|
|3.||Townsend, Danyelle M: 3 articles (01/2010 - 04/2008)|
|4.||Montero, Alberto J: 1 article (05/2012)|
|5.||Feng, Wei: 1 article (05/2012)|
|6.||Zidan, Abdel-Aziz: 1 article (05/2012)|
|7.||Zhou, Daohong: 1 article (05/2012)|
|8.||Diaz-Montero, C Marcela: 1 article (05/2012)|
|9.||Shao, Lijian: 1 article (05/2012)|
|10.||Wang, Yong: 1 article (05/2012)|
07/01/2008 - "NOV-002 is a mechanistically novel agent with potential for ameliorating hematologic toxicity and enhancing efficacy when used in combination with standard chemotherapy to treat cancer patients."
02/01/2012 - "The addition of NOV-002 to chemotherapy has been shown to increase anti-tumor efficacy in animal models and some early phase oncology trials. "
05/01/2012 - "The oxidized glutathione mimetic NOV-002 is a unique anti-tumor agent that not only has the ability to inhibit tumor cell proliferation, survival, and invasion, but in some settings can also ameliorate cytotoxic chemotherapy-induced hematopoietic and immune suppression. "
01/01/2010 - "Previous and ongoing clinical studies demonstrate a significantly improved 1-year survival and decreased tumor progression rates in non-small cell lung (NSCLC) and ovarian cancer patients when NOV-002 was included in cisplatin containing regimens. "
02/01/2012 - "NOV-002 (a formulation of disodium glutathione disulfide) modulates signaling pathways involved in tumor cell proliferation and metastasis and enhances anti-tumor immune responsiveness in tumor models. "
|2.||Ovarian Neoplasms (Ovarian Cancer)
|3.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
04/15/2008 - "NOV-002 is a novel glutathione disulfide mimetic that when administered in combination with standard chemotherapeutic regimens has resulted in increased efficacy (survival, tumor response) and improved tolerance to chemotherapy (e.g., hematologic recovery) in advanced non-small cell lung cancer patients. "
|4.||Breast Neoplasms (Breast Cancer)
02/01/2012 - "We evaluated the clinical effects of NOV-002 in primary breast cancer, whether adding NOV-002 to standard preoperative chemotherapy increased pathologic complete response rates (pCR) at surgery, and determined whether NOV-002 mitigated hematologic toxicities of chemotherapy and whether levels of myeloid derived suppressor cells (MDSC) were predictive of response. "
02/01/2012 - "Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II-IIIc breast cancer."
02/01/2012 - "Forty-one women with newly diagnosed stages II-IIIc HER-2 negative breast cancer received doxorubicin-cyclophosphamide followed by docetaxel (AC → T) every 3 weeks and concurrent daily NOV-002 injections. "
|5.||Neoplasm Metastasis (Metastasis)
|2.||Glutathione Disulfide (GSSG)
|1.||Drug Therapy (Chemotherapy)